BioSpace News Archive

Acutus Medical announced the appointment of John Sheridan to the Company’s Board of Directors effective March 17, 2021.

Randomized, double-blind Phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients (GIV-IN PV TRIAL) with over 100 participating international clinical sites to be initiated by mid-2021

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company has licensed the compound MSB-3163 from Dr. Richard Gallo’s laboratory at the University of California San Diego School of Medicine.

These results are confirmation of significant growth in 2020 for Chiesi, which has been a Benefit Company since 2018 and Certified B Corporation™ since 2019.

Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will participate in a virtual panel discussion and present a corporate overview at the Benzinga Biotech Small Cap Conference

Red Cell Partners, a newly formed investment firm backing disruptive technology-led companies in health care and defense, today announced its launch.

Petros Pharmaceuticals, Inc. (Petros or the Company) (NASDAQ: PTPI), a leading provider of therapeutics for men’s health, today announced the publication of preliminary research on the investigational use of Stendra® (avanafil) for endothelial function in men with erectile dysfunction (ED).

Janux Therapeutics today announced the appointment of Vickie Capps and Sheila Gujrathi, M.D., as independent members of the Company’s Board of Directors.

MediXall Group, Inc., a healthcare solutions provider, is pleased to announce the delivery of educational content through the For the Health of It blog created and managed by its subsidiary Health Karma.